Anju Software Introduces AI Ecosystem for Rapid Clinical Trial Setup
Anju Software has introduced clinexa, an AI-driven ecosystem aimed at transforming clinical trial setups, announced in a press release. This innovative platform automates the conversion of clinical protocols into trial-ready databases, significantly reducing the time required from months to just days.
The initial release of clinexa focuses on automating protocol ingestion and generating essential trial components such as casebooks, edit checks, and validation materials. This automation is designed to accelerate the database creation and validation process, enabling sponsors and Contract Research Organizations (CROs) to launch trials more swiftly and concentrate on patient care.
Key benefits of clinexa include a 90% reduction in study build times, a 50% decrease in queries due to NLP-powered edit checks, and a threefold increase in productivity for data managers. The platform ensures data sovereignty, with Anju Software not monetizing customer data.
The introduction of clinexa addresses the costly and time-consuming nature of clinical trial startups, offering a critical edge in quality and compliance for life sciences organizations.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read more